Last reviewed · How we verify
CimetrA-2
CimetrA-2 is a synthetic cannabinoid receptor agonist.
CimetrA-2 is a synthetic cannabinoid receptor agonist. Used for Treatment-resistant epilepsy.
At a glance
| Generic name | CimetrA-2 |
|---|---|
| Also known as | CimetrA- 2 drug administration |
| Sponsor | MGC Pharmaceuticals d.o.o |
| Drug class | cannabinoid receptor agonist |
| Target | CB1/CB2 receptors |
| Modality | Small molecule |
| Therapeutic area | Pain management |
| Phase | Phase 3 |
Mechanism of action
CimetrA-2 acts by binding to cannabinoid receptors in the body, which can help to reduce inflammation and alleviate symptoms associated with certain medical conditions.
Approved indications
- Treatment-resistant epilepsy
Common side effects
- Nausea
- Dizziness
- Fatigue
Key clinical trials
- Study Designed to Evaluate the Effect of CimetrA in Patients Diagnosed With COVID-19 (PHASE2)
- Clinical Study Designed to Evaluate the Effect of CimetrA in Patients Diagnosed With COVID-19 (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |